HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa).

Abstract
GGF2 is a recombinant human neuregulin-1β in development for chronic heart failure. Phase 1 clinical trials of GGF2 were put on hold when transient elevations in serum aminotransferases and total bilirubin were observed in 2 of 43 subjects who received single doses of GGF2 at 1.5 or 0.378 mg/kg. However, aminotransferase elevations were modest and not typical of liver injury sufficient to result in elevated serum bilirubin. Cynomolgus monkeys administered a single 15 mg/kg dose of GGF2 had similar transient elevations in serum aminotransferases and bilirubin as well as transient elevations in serum bile acids. However, no hepatocellular necrosis was observed in liver biopsies obtained during peak elevations. When sandwich-cultured human hepatocytes were treated with GGF2 for up to 72 h at concentrations approximately 0.8-fold average plasma Cmax for the 0.378 mg/kg dose, no cytotoxicity was observed. Gene expression profiling identified approximately 50% reductions in mRNAs coding for bilirubin transporters and bile acid conjugating enzymes, as well as changes in expression of additional genes mimicking the interleukin-6-mediated acute phase response. Similar gene expression changes were observed in GGF2-treated HepG2 cells and primary monkey hepatocytes. Additional studies conducted in sandwich-cultured human hepatocytes revealed a transient and GGF2 concentration-dependent decrease in hepatocyte bile acid content and biliary clearance of taurocholate without affecting biliary taurocholate efflux. Taken together, these data suggest that GGF2 does not cause significant hepatocellular death, but transiently modifies hepatic handling of bilirubin and bile acids, effects that may account for the elevations in serum bilirubin observed in the clinical trial subjects.
AuthorsMerrie Mosedale, Donald Button, Jonathan P Jackson, Kimberly M Freeman, Kenneth R Brouwer, Anthony O Caggiano, Andrew Eisen, Jennifer F Iaci, Tom J Parry, Ric Stanulis, Maya Srinivas, Paul B Watkins
JournalToxicological sciences : an official journal of the Society of Toxicology (Toxicol Sci) Vol. 161 Issue 2 Pg. 401-411 (02 01 2018) ISSN: 1096-0929 [Electronic] United States
PMID29069498 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© The Author 2017. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: [email protected].
Chemical References
  • Bile Acids and Salts
  • Neuregulin-1
  • cimaglermin
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Bilirubin
Topics
  • Animals
  • Bile Acids and Salts (blood)
  • Bile Ducts (drug effects, metabolism, pathology)
  • Bilirubin (blood)
  • Biological Transport
  • Cell Survival (drug effects)
  • Clinical Trials, Phase I as Topic
  • Cytochrome P-450 CYP3A (genetics)
  • Hep G2 Cells
  • Hepatocytes (drug effects, metabolism, pathology)
  • Humans
  • Liver (drug effects, metabolism, pathology)
  • Macaca fascicularis
  • Male
  • Neuregulin-1 (adverse effects)
  • Primary Cell Culture
  • Toxicogenetics
  • Transcriptome (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: